Predicting prostate cancer many years before diagnosis: how and why?
Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis...
Príomhchruthaitheoirí: | Vickers, A, Lilja, H |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2012
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
de réir: Lilja, H, et al.
Foilsithe / Cruthaithe: (2007) -
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
de réir: Lilja, H, et al.
Foilsithe / Cruthaithe: (2008) -
We need a better marker for prostate cancer. How about renaming PSA?
de réir: Vickers, A, et al.
Foilsithe / Cruthaithe: (2012) -
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
de réir: Ulmert, D, et al.
Foilsithe / Cruthaithe: (2008) -
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
de réir: Lilja, H, et al.
Foilsithe / Cruthaithe: (2011)